Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Covid-19 Updates
stale
Added 4 years ago
Read More
#ASX Announcements
stale
Added one year ago

After a shock period including sudden resignation of the CEO for personal reasons, which saw a selloff similar to Megaport when their CEO resigned, ALS has managed to lift guidance and still sees strong trading conditions

Underlying net profit after tax (NPAT) guidance range to between $312 million and $322 million, up from $300 million to $320 million

Probably a good option to be in ALS if you don't want risk owning a mining company in gold or base metals but prefer some indirect leverage to mining and other industries via their testing and analysis services.

Still have a high debt to equity ratio though. Can't seem to shake that monkey off their back.

[held]

Read More
#Financials
stale
Last edited 11 months ago

ALS figures beat the market consensus and provided a bullish outlook. However it seems more were focused on increase in debt and intangibles.

e0f3f113c1d6c435515ebe500988f9df1c281a.png

I understand ALS provides an "essential service" via laboratory testing etc but can't understand why they are not reducing their debt. On the flipside I was taught that debt increases interest tax shields and possibly has a positive impact on free cash flow.

Ord Minnett also downgraded to sell based on not being able to meet capital costs with earnings from spending big trying to expand their global operations to meet the boom in resources and probably explains why share price fell despite the positive outlook

Other negative include the Nuvisan life sciences acquisition which lost money in the last 6 months and dragged overall performance for life sciences. ALS blamed performance on economic headwinds which is a bit surprising.

8a2ddc7cfb706bd4e551671bd3536e0c2b0b83.png

[held]

Read More
#Bear Case
stale
Added 9 months ago

Noticed the incoming CEO doesn't hold

Lots of sells from the instos recently so I decided to follow early last week after EOFY and take the profit left.

Good tailwinds but let down by debt pile and poor execution of Nuvisan business. Possibly Nuvisan is more cyclical than expected

Will watch from the sidelines for now

[not held]

Read More
Valuation of $8.40
stale
Added 5 years ago
Attractive valuation has triggered interest. Operating cash-flows rising 17.8%, offsetting reasonable debt levels with net debt to equity at 57%. Management expect FY20 revenue growth to be in the ‘double-digits' with expectations for increase capital raisings to benefit in 2H20. Acquisitions are expected to drive growth in the Life Science division, although growth in the Industrial segment is likely to remain soft in FY20. Watch for further clarity on the 1H20 is expected to be provided at the AGM on 31 July 2019 (including guidance).
Read More